New obesity drug HRS-5817 enters early human testing
NCT ID NCT07238647
First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-phase study tests a single injection of HRS-5817 in 40 obese adults aged 18-55 with a BMI of 30-40. The main goal is to check safety and side effects, not to cure obesity. Researchers will also measure how the drug moves through the body and how the immune system responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linear
Perth, Western Australia, 6027, Australia
Conditions
Explore the condition pages connected to this study.